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In 1986-1987,  the research directors of major and medium-sized US 
biotechnology companies  agreed on the wisdom of developing 
cooperative research arrangements in protein engineering, bio- 
process and large-scale animal  cell culture technologies. However, 
upper-level corporate managers were not convinced that colla- 
borative approaches would be essential for the maintenance of long- 
term competit iveness of the US biotechnology industry. Now that 
cooperative research efforts in Japan and Europe are beginning to 
challenge US supremacy in biotechnology, the prospect of US 
industry consortia may be viewed in a kinder light. We believe that 
the US government has a key role to play in providing both f inancial  
and logistical support. 
During 1986-1987 we invited re- 
search directors from several dozen 
major biotechnology companies to 
explore benefits that might be 
derived from consortia conducting 
joint research on problems they 
identified as common barriers to 
achieving marketable products. The 
structure of the consortium was to be 
developed by the participating 
members. A brief account of these 
activities appeared earlier 1. At that 
time, one of us (DLO) had recently 
concluded a report for US govern- 
mental  agencies on Japanese activi- 
ties in the field of biotechnology 
(JTECH Report)Z; the other (CFF) was 
(and is) Director of the UCLA 
Symposia on Molecular and Cellular 
Biology. In parallel with the meeting 
of corporate research directors, sixty 
members of university research 
establishments and governmental 
agencies also met (at the Keystone 
Center, Keystone, Colorado) to 
examine substantive policy issues 
and possible roles for public sector 
scientists. 
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These early meetings concentrated 
on identifying technologies that limit 
commercialization of new biotech- 
nology products. A list of limiting 
technologies was initially created 
from extensive input from the cor- 
porations. The consensus view was 
that protein engineering, large-scale 
animal cell culture, and bioproces- 
sing were major obstacles to product 
development. Protein engineering 
emerged as the most likely candidate 
for a consortium, the objective of 
which would be cooperative devel- 
opment of improved technologies for 
producing altered or novel proteins 
with commercial value. 
There was general agreement that 
problems such as determining the 
rules governing protein folding 
would be more likely to yield to 
cooperative than to individual ef- 
forts. However, few of the companies 
were prepared to tackle the problems 
inherent in creating cooperative 
research consortia without greater 
incentives from the US government. 
Around the same time and on several 
occasions, the concept of an in- 
dustry-driven cooperative research 
arrangement was on the agenda of 
the Pharmaceutical Manufacturers' 
Association (PMA) research com- 
mittee; the outcome was similarly 
inconclusive. 
It should be noted that, for the most 
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part, the corporate research directors 
were receptive and optimistic about 
research consortia and worked hard 
to develop a feasible plan. It became 
increasingly clear, however, that 
when they took this idea back to their 
corporate directors, for a variety of 
reasons, the corporations were not 
yet prepared to tackle the problem. 
What were the barriers to a 
consortium? 
Ron Cape, chairman of Cetus Corp. 
was quoted as saying 'There's an 
accumulation of detailed reasons at 
the nitty-gritty level that present 
quite a formidable barrier' to the 
development of a research consor- 
t ium 1. These included corporate 
concern over patent rights, propri- 
etary control and anti-trust regula- 
tions. There was also no agreement 
on which proteins were appropriate 
subjects for generic research. Ad- 
ditional concerns which surfaced 
during discussion included: 
• corporate preferences for tackling 
smaller parts of a problem and 
owning the solution outright; 
• the perception that milestones set 
by a common organizational struc- 
ture would stifle research essential to 
a member's continued interest; 
• the feeling that larger, established 
companies would derive less benefit 
than smaller firms (the consortium 
would contribute proportionally 
less to the company's overall 
research effort); 
• companies close to the consortium 
site might benefit more; 
• the best corporate scientists might 
be retained for in-house work rather 
than released to the consortium; 
• significant organizational support 
and funding are unavailable from 
government; 
• there are no good models to 
emulate (cultural differences may 
preclude direct comparisons with 
successful Japanese initiatives). 
Protein engineering consortia 
outside the US 
US dominance of biotechnology 
research has been eroded substan- 
tially by research efforts in Japan 2 
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and Western Europe. This may reflect 
changes in funding for biotechnology 
research; this increased by 50% in 
Western Europe and 68% in Japan 
from 1986 to 1987, butby only 19% in 
the US. Past US experiences in the 
automobile and semiconductor 
industries show that a sizable tech- 
nological lead can vanish rapidly. 
Japan's Protein Engineering Research 
Institute 
MITI, the Japanese government 
Ministry of International Trade and 
Industry, plays a key role in me- 
diating transfer of technology to the 
market place. In April 1986, MITI 
catalysed the formation of the Protein 
Engineering Research Institute 
(PERI) 3, a 14-company consortium 
which recently moved into new 
quarters near Osaka. Approximately 
$100 million has been committed to 
PERI by the government and the 
companies over a 10-year period and 
member firms send scientists to 
engage in cooperative research at 
PERI for periods of 3-5 years. The 
aim of PERI is to enhance the ability 
to design novel proteins with 
medical or biotechnological appli- 
cations. PERI is organized into the 
following five research departments: 
• determination of three-dimen- 
sional protein structure; 
• structure prediction and design 
using molecular dynamic analysis 
and computer modelling; 
• protein remodelling through site- 
directed mutagenesis and expression 
optimization for large-scale produc- 
tion; 
• large-scale protein purification; 
• development and management of 
computer databases and specialized 
software. 
In PERI, the Japanese are addres- 
sing the same high-priority list of 
technologies upon which US bio- 
technology research companies 
reached consensus independently in 
our initiative. Any new technology 
developed by PERI is available to all 
14 companies for their proprietary 
protein and peptide products, and 
patents are held by the consortium 
and licensed semi-exclusively to the 
member firms. The US commitment 
to protein engineering is certainly 
there; many companies have made 
substantial investments. However, in 
the standard (current) US approach, 
each company will develop each 
aspect of technology independently; 
repeated reinvention of the wheel. 
Thus, in each company, major re- 
sources will be committed to de- 
velop, for instance, the software and 
computer systems for a first-class 
computational chemistry facility for 
macromolecular modelling and data- 
base management. Clearly, there 
would be advantages in sharing such 
a facility. 
In October 1986, the government 
agency JDRC (the Research Develop- 
ment Corporation of Japan), created 
the High Technology Consortium 
System (HTCS) 4. This was to sys- 
tematically exploit the basic research 
generated in the ERATO (Exploratory 
Research for Advanced Technology) 
program 5 launched by JRDC in 19813. 
The HTCS also plans to initiate other 
consortia to develop intellectual 
property emerging from national 
research laboratories, universities 
and other government research 
organizations. 
US academic institutions are 
seldom effective in licensing their 
patented technologies, and substan- 
tial efforts may be required to 
overcome this barrier. Some univer- 
sity patent and licensing offices, 
(e.g. Stanford's) have been highly 
effective and might serve as models 
for other institutions. 
The UK Protein Engineering 'Club' 
In 1985, the UK's Biotechnology 
Directorate of the Science and Engin- 
eering Research Council (SERC) and 
four British companies launched the 
Protein Engineering 'Club '~. This 
club supports research initiatives at 
universities with around a third of 
the funds coming from the com- 
panies. SERC has also formed a 
similar club to support university 
research in animal cell physiology. 
These efforts provide a mechanism 
for industrial support of university 
research. In return, the companies 
have a 'hotline' to the results of 
leading researchers which should 
improve the transfer of technology 
for commercial product develop- 
ment. 
Can US industry adopt these models? 
Many US pharmaceutical corpor- 
ations take the view that Japan's 
effectiveness with research consortia 
such as PERI is the property of a 
unique cultural background. While 
the role of culture in cooperative 
research may be significant, it is 
difficult to evaluate. We cannot 
conclude that cultural differences 
between Japan or the UK and the US 
preclude development of a style of 
effective consortium unique to the 
US. 
Direct roles for go vernm en t agencies 
The most obvious missing in- 
gredient in our attempts to catalyse 
development of research consortia 
was government participation. In our 
early discussions, the idea of includ- 
ing governmental agencies was dis- 
cussed, but rejected by several cot'- 
porate representatives on the 
grounds that administration and 
decision-making ability of a con- 
sortium would be hampered by 
bureaucracy. 
Examination of model consortia 
formed in Japan and England 
revealed two important roles for 
government. In each case, a govern- 
ment agency provided the leadership 
necessary for coordinating and cata- 
lysing the organization of the consor- 
tium and, equally if not more 
important, up to 70% of the initial 
financing. 
Long-range objectives 
The support and stability afforded 
by government participation is vital 
to consortia developing technologies 
such as protein engineering because 
the objectives are on a more distant 
horizon than those normally per- 
ceived by US firms. While US 
corporations generally limit their 
business plans to 3 5 years, it is not 
uncommon for Japanese firms to look 
10 years or so into the future. 
Japanese business has accurately 
assessed future markets in the auto- 
motive and electronics industries. 
There is no reason to believe that they 
are off the mark in targeting protein 
engineering as a key technology for 
commercializing biotechnology. 
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US corporation cooperative efforts 
outside biotechnology 
Therese Welter's article 7 contains a 
comprehensive record of cooperative 
efforts in US research consortia such 
as the Microelectronics and Com- 
puter Technology Corp. (MCC), 
Semiconductor Research Corp. 
(SRC), National Center for Manufac- 
turing Sciences, Bell Communi- 
cations Research and Sematech. Each 
of these consortia was initiated 
largely in response to penetration of 
once secure US markets by other 
countries. Have these consortia been 
effective? They have certainly gener- 
ated products. For instance, in April 
1985 (earlier than expected), MCC 
announced their Proteus computer 
program for developing expert sys- 
tems; consequently, Honeywell In- 
formation Systems, Inc. developed 
an expert system to design and place 
components on a circuit board. 
Boeing Electronics has established 
four laboratories to support MCC- 
transferred technologies. 
The existing consortia also appear 
to dispel the myth that 'companies 
with huge in-house efforts benefit 
less than those without'. Quite the 
reverse; corporations with the largest 
internal commitment are clearly in 
the best position to take advantage of 
new technologies and transfer them 
rapidly to the market place. 
New research approaches for 
biotechnology 
Biology now has the tools to 
attempt major projects such as the 
mapping and sequencing of the 
Human Genome s. These projects will 
require an organized interdisciplinary 
approach with major resource com- 
mitments. One of the first steps in 
this approach will be gaining experi- 
ence on smaller projects, such as 
sequencing the smaller genomes of E. 
coli and then yeast. 
The conventional US approach to 
research funding is to make competi- 
tive grants available for supporting 
the best proposals. This may not be 
appropriate as a mechanism for 
funding genome sequencing. In 
Japan, a cooperative research ap- 
proach has already been imple- 
mented, coordinated and directed by 
a government agency. Thus, a library 
of DNA fragments covering the E. coli 
chromosome has been divided 
among thirty universities, and each 
has been assigned the sequencing of 
a separate portion. The completed 
sequence of E. coli may soon be 
available from Japan. 
Some current problems in biology, 
notably those of a broad and shallow 
nature, can benefit from an organized 
cooperative approach. These should 
complement rather than replace 
individual investigator-initiated 
(narrow and deep) research projects. 
It will be increasingly important in 
the future for the US to identify the 
right mix between these types of 
projects. It is precisely this dilemma 
that is associated with the huge 
resource commitments required for 
'Big Science' projects. The US des- 
perately needs to develop a sound 
and positive National Science Policy 
to meet this challenge. 
National science policy 
In our efforts to catalyse the 
formation of US biotechnology con- 
sortia, we did not find that the US 
government was prepared to play a 
highly active role in direct support of 
biotechnology commercialization in 
the US. This is in striking contrast to 
initiatives already under way in 
Japan, the UK and elsewhere. It is 
clear that the US government could 
play a more direct role in the 
development and commercialization 
of technology. We propose that the 
US government takes immediate 
steps to develop a rational, coherent 
National Science Policy by forming a 
high level agency specifically 
assigned that task. This agency 
should complement the highly suc- 
cessful individual projects with co- 
ordinated efforts directed at the 
development of new and improved 
capabilities in areas where the cur- 
rent level of technology is limiting 
progress. It should also catalyse 
industry input to develop consensus 
views on technology development 
requirements and coordinate both 
public and private sector efforts to 
meet these challenges. 
We can no longer ignore the 
messages of Roy and Shapley in 'Lost 
at the Frontier'9; our science policy 
has been too long adrift like a vessel 
at sea with no captain. Now that 
pressure is being increased, the idea 
of forming US cooperative research 
consortia to meet generic research 
needs has become more attractive. 
An effective National Science Policy 
will meet this issue head-on by 
creating means to enable private and 
public sector scientists jointly to 
identify essential research endpoints 
and subscribe to research plans that 
achieve them expeditiously. 
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